As of 2024-12-12, the EV/EBITDA ratio of PTC Therapeutics Inc (PTCT) is 206.93. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. PTCT's latest enterprise value is 5,690.42 mil USD. PTCT's TTM EBITDA according to its financial statements is 27.50 mil USD. Dividing these 2 quantities gives us the above PTCT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative Enterprise Value.
| Range | Selected | |
| Trailing P/E multiples | 16.0x - 19.3x | 17.2x |
| Forward P/E multiples | 15.8x - 24.0x | 18.2x |
| Fair Price | (18.49) - (15.54) | (17.80) |
| Upside | -137.2% - -131.3% | -135.8% |
| Date | EV/EBITDA |
| 2024-12-04 | 207.46 |
| 2024-12-03 | 208.67 |
| 2024-12-02 | 213.66 |
| 2024-11-29 | 190.69 |
| 2024-11-27 | 194.14 |
| 2024-11-26 | 196.67 |
| 2024-11-25 | 188.20 |
| 2024-11-22 | 188.87 |
| 2024-11-21 | 187.92 |
| 2024-11-20 | 185.31 |
| 2024-11-19 | 178.01 |
| 2024-11-18 | 177.65 |
| 2024-11-15 | 177.65 |
| 2024-11-14 | 186.48 |
| 2024-11-13 | 191.11 |
| 2024-11-12 | 192.77 |
| 2024-11-11 | 193.47 |
| 2024-11-08 | 191.81 |
| 2024-11-07 | 188.11 |
| 2024-11-06 | 188.73 |
| 2024-11-05 | 182.25 |
| 2024-11-04 | 180.90 |
| 2024-11-01 | 181.13 |
| 2024-10-31 | 179.58 |
| 2024-10-30 | 181.66 |
| 2024-10-29 | 186.82 |
| 2024-10-28 | 181.16 |
| 2024-10-25 | 181.91 |
| 2024-10-24 | 183.74 |
| 2024-10-23 | 186.77 |
| 2024-10-22 | 177.90 |
| 2024-10-21 | 175.43 |
| 2024-10-18 | 177.28 |
| 2024-10-17 | 171.42 |
| 2024-10-16 | 170.55 |
| 2024-10-15 | 172.97 |
| 2024-10-14 | 177.40 |
| 2024-10-11 | 177.00 |
| 2024-10-10 | 175.57 |
| 2024-10-09 | 179.64 |
| 2024-10-08 | 181.97 |
| 2024-10-07 | 165.76 |
| 2024-10-04 | 166.07 |
| 2024-10-03 | 166.82 |
| 2024-10-02 | 169.80 |
| 2024-10-01 | 168.73 |
| 2024-09-30 | 171.68 |
| 2024-09-27 | 172.97 |
| 2024-09-26 | 173.25 |
| 2024-09-25 | 170.38 |